The California Institute for Regenerative Medicine (CIRM) is excited to announce the appointment of Jonathan “JT” Thomas, PhD, JD, as our new President and CEO. JT brings extensive experience and a deep commitment to our mission. Previously, he served as the Chair of the Independent Citizens' Oversight Committee (ICOC) for 12 years and, most recently, … Continue reading CIRM Welcomes Jonathan Thomas as New President and CEO
CIRM News
CIRM celebrates landmark 100+ clinical trial awards
Photo credit: Barbara Ries for UCSF, Jaquell Chandler, and OHSU/Christine Torres Hicks The California Institute for Regenerative Medicine (CIRM), California’s Stem Cell Agency and the world’s largest institution dedicated to regenerative medicine reached a milestone when it approved funding for its 100th clinical trial. At the February Independent Citizens’ Oversight Committee (ICOC) meeting, the board … Continue reading CIRM celebrates landmark 100+ clinical trial awards
CIRM awards more than $56 million for clinical research aimed at treating Parkinson’s disease, autoimmune conditions and a variety of cancers
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $56 million to fund various clinical research aimed at treating Parkinson’s disease, autoimmune conditions and a variety of cancers. The awards will support seven projects—five clinical trials and two preclinical projects—in the Agency’s clinical program which provides funding for … Continue reading CIRM awards more than $56 million for clinical research aimed at treating Parkinson’s disease, autoimmune conditions and a variety of cancers
CIRM invests $50 million in clinical research, including trial for vision loss
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, today awarded $50.1 million to fund clinical-stage research projects aimed at advancing stem cell and gene therapy treatments for a variety conditions ranging from neurodegenerative diseases and blood cancers to HIV/AIDS. The awards will support six projects in the Agency’s … Continue reading CIRM invests $50 million in clinical research, including trial for vision loss
CIRM welcomes two additions to its leadership team
Left to right: Rafael Aguirre-Sacasa, General Counsel and Koren Temple-Perry, Senior Director of Marketing Communications The California Institute for Regenerative Medicine (CIRM) continues to build its world class team to deliver the full potential of regenerative medicine to the people of California and around the world. CIRM is pleased to welcome two new members to its … Continue reading CIRM welcomes two additions to its leadership team
Apply Now! Discovery Stage Funding + Webinar on April 7
The California Institute for Regenerative Medicine (CIRM) is pleased to announce the opening of our next round of Quest Awards (DISC2) for discovery stage research. The purpose of the Quest Awards is to promote discovery of promising new stem cell-based and/or gene therapy technologies that could be translated to enable broad use and ultimately, improve patient care. The expected … Continue reading Apply Now! Discovery Stage Funding + Webinar on April 7
CIRM welcomes new Chair, bids farewell to Art Torres and Jonathan Thomas
Dr. Vito Imbasciani was sworn in as the new Chair of the Board of the California Institute for Regenerative Medicine (CIRM) at its March meeting. Imbasciani (pictured above at left) was elected to the six-year term at CIRM’s January Board meeting. He will replace outgoing chair Jonathan Thomas, who has served in the position since 2011. “My experience … Continue reading CIRM welcomes new Chair, bids farewell to Art Torres and Jonathan Thomas
California agency invests $4 million in stem cell treatment for Parkinson’s Disease
The California Institute for Regenerative Medicine (CIRM) is investing $4 million in a late-stage preclinical project by Ryne Bio aiming to improve treatment for Idiopathic Parkinson's disease (PD). PD is characterized by a loss of dopamine producing neurons that result in motor symptoms, such as dyskinesias (involuntary, erratic, writhing movements of the face, arms, legs … Continue reading California agency invests $4 million in stem cell treatment for Parkinson’s Disease
Dr. Vito Imbasciani elected Chair of CIRM
Dr. Vito Imbasciani elected Chair of the California Institute for Regenerative Medicine (CIRM). Voters created CIRM in 2004 and renewed its funding in 2020 to advance stem cell and regenerative medicine research. Board Support At January’s meeting, the agency’s 35‑member Governing Board elected Imbasciani to a six‑year term. He succeeds Jonathan Thomas, who has served … Continue reading Dr. Vito Imbasciani elected Chair of CIRM
Funding development of a vaccine for acute myelogenous leukemia (AML)
Dr. Karin Gaensler. Photo credit: Steve Babuljak/UCSF Adult acute myelogenous leukemia—also known as acute myeloid leukemia (AML)—is a blood cancer in which the bone marrow makes a large number of abnormal blood cells. About 20,000 new cases of AML are diagnosed each year in the US with a 5-year survival rate of around 29%. In … Continue reading Funding development of a vaccine for acute myelogenous leukemia (AML)